🎉 M&A multiples are live!
Check it out!

Heron Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Heron Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Heron Therapeutics Overview

About Heron Therapeutics

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.


Founded

1983

HQ

United States of America
Employees

122

Website

herontx.com

Financials

LTM Revenue $148M

LTM EBITDA $8.6M

EV

$412M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Heron Therapeutics Financials

Heron Therapeutics has a last 12-month revenue of $148M and a last 12-month EBITDA of $8.6M.

In the most recent fiscal year, Heron Therapeutics achieved revenue of $144M and an EBITDA of -$5.1M.

Heron Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Heron Therapeutics valuation multiples based on analyst estimates

Heron Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $127M $144M XXX XXX XXX
Gross Profit $52.8M $61.9M XXX XXX XXX
Gross Margin 42% 43% XXX XXX XXX
EBITDA -$104M -$5.1M XXX XXX XXX
EBITDA Margin -82% -4% XXX XXX XXX
Net Profit -$182M -$111M XXX XXX XXX
Net Margin -143% -77% XXX XXX XXX
Net Debt $134M $145M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Heron Therapeutics Stock Performance

As of April 15, 2025, Heron Therapeutics's stock price is $2.

Heron Therapeutics has current market cap of $294M, and EV of $412M.

See Heron Therapeutics trading valuation data

Heron Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$412M $294M XXX XXX XXX XXX $-0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Heron Therapeutics Valuation Multiples

As of April 15, 2025, Heron Therapeutics has market cap of $294M and EV of $412M.

Heron Therapeutics's trades at 2.8x LTM EV/Revenue multiple, and 48.0x LTM EBITDA.

Analysts estimate Heron Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Heron Therapeutics and 10K+ public comps

Heron Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $412M XXX XXX XXX
EV/Revenue 2.9x XXX XXX XXX
EV/EBITDA -81.6x XXX XXX XXX
P/E -21.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -17.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Heron Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Heron Therapeutics Valuation Multiples

Heron Therapeutics's NTM/LTM revenue growth is 11%

Heron Therapeutics's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Heron Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Heron Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Heron Therapeutics and other 10K+ public comps

Heron Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 14% XXX XXX XXX XXX
EBITDA Margin -4% XXX XXX XXX XXX
EBITDA Growth -95% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 8% XXX XXX XXX XXX
Revenue per Employee $1.2M XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue 33% XXX XXX XXX XXX
G&A Expenses to Revenue 37% XXX XXX XXX XXX
R&D Expenses to Revenue 12% XXX XXX XXX XXX
Opex to Revenue 81% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Heron Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Heron Therapeutics M&A and Investment Activity

Heron Therapeutics acquired  XXX companies to date.

Last acquisition by Heron Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Heron Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Heron Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Heron Therapeutics

When was Heron Therapeutics founded? Heron Therapeutics was founded in 1983.
Where is Heron Therapeutics headquartered? Heron Therapeutics is headquartered in United States of America.
How many employees does Heron Therapeutics have? As of today, Heron Therapeutics has 122 employees.
Who is the CEO of Heron Therapeutics? Heron Therapeutics's CEO is Mr. Craig A. Collard.
Is Heron Therapeutics publicy listed? Yes, Heron Therapeutics is a public company listed on NAS.
What is the stock symbol of Heron Therapeutics? Heron Therapeutics trades under HRTX ticker.
When did Heron Therapeutics go public? Heron Therapeutics went public in 1987.
Who are competitors of Heron Therapeutics? Similar companies to Heron Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Heron Therapeutics? Heron Therapeutics's current market cap is $294M
What is the current revenue of Heron Therapeutics? Heron Therapeutics's last 12-month revenue is $148M.
What is the current EBITDA of Heron Therapeutics? Heron Therapeutics's last 12-month EBITDA is $8.6M.
What is the current EV/Revenue multiple of Heron Therapeutics? Current revenue multiple of Heron Therapeutics is 2.8x.
What is the current EV/EBITDA multiple of Heron Therapeutics? Current EBITDA multiple of Heron Therapeutics is 48.0x.
What is the current revenue growth of Heron Therapeutics? Heron Therapeutics revenue growth between 2023 and 2024 was 14%.
Is Heron Therapeutics profitable? Yes, Heron Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.